Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal buprenorphine.

Hannah C Evans1, Stephanie E Easthope

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.

Drugs·2006
Same author

Rotigotine: in Parkinson's disease.

CNS drugs·2005
Same author

Darbepoetin alfa: its use in anemia associated with chronic kidney disease.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2005
Same author

Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.

Treatments in endocrinology·2005
Same author

Intranasal sumatriptan: in adolescents with migraine.

CNS drugs·2005
Same author

Spotlight on gefitinib in non-small-cell lung cancer.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Transdermal buprenorphine patches offer effective pain relief for chronic pain patients, reducing the need for rescue medication. This opioid analgesic was generally well-tolerated, with adverse events typical of opioid therapy.

Area of Science:

  • Pharmacology
  • Pain Management
  • Drug Delivery Systems

Background:

  • Buprenorphine is a lipophilic opioid analgesic.
  • A transdermal matrix patch formulation of buprenorphine is now available in three dosage strengths (35, 52.5, and 70 micro g/h) for 72-hour continuous release.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of transdermal buprenorphine in patients with chronic pain.
  • To assess the requirement for rescue medication and overall pain relief compared to placebo.

Main Methods:

  • Double-blind, placebo-controlled, randomized trials were conducted.
  • Patients received transdermal buprenorphine at varying dosages or placebo.
  • Efficacy was measured by satisfactory analgesia and minimal need for rescue medication (

Related Experiment Videos

Main Results:

  • 34-50% of patients on transdermal buprenorphine achieved satisfactory analgesia with minimal rescue medication, compared to 31% on placebo.
  • In patients previously treated with weak opioids or morphine, 36.6% and 47.5% on 35 and 52.5 micro g/h patches, respectively, experienced satisfactory analgesia (p
  • Over 50% of patients on transdermal buprenorphine showed reduced need for rescue medication; greater pain relief, reduced intensity, and improved sleep were observed.

Conclusions:

  • Transdermal buprenorphine provides effective analgesia for chronic pain, with a reduced need for rescue medication.
  • The treatment was generally well-tolerated, with adverse events consistent with opioid therapy.
  • Transdermal buprenorphine represents a viable option for managing chronic pain effectively and safely.